CJC-1295 with DAC vs Mazdutide
Well Studied vs Extensively Studied
monitor Mechanism-based · 47% Both CJC-1295 with DAC and Mazdutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
CJC-1295 with DAC Mazdutide
Weight 3,647.28 Da 4,563.1 Da
Half-life 6-8 days 6-8 days
Chain 30 amino acids 33 amino acids
Type GHRH analog with DAC Oxyntomodulin analog with fatty acid conjugation
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Mazdutide
01 Up to 20% body weight loss
02 Superior glycemic control versus semaglutide
03 Increased energy expenditure via glucagon receptor activation
04 Improved cardiometabolic markers (BP, lipids, liver fat)
05 Once-weekly injection convenience
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Mazdutide
Start 1.5-3mg weekly, titrate up to 6-9mg based on response / Once weekly injection
Weight loss initiation (3mg target) 1.5mg → 3mg Once weekly
Weight loss progression (4.5mg target) 1.5mg → 3mg → 4.5mg Once weekly
Weight loss optimization (6mg target) 2mg → 4mg → 6mg Once weekly
Maximum weight loss (9mg target) 3mg → 6mg → 9mg Once weekly
T2D management (mild-moderate) 3-4.5mg weekly Once weekly
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Mazdutide
Nausea (mild-moderate, typically improves over time)
Diarrhea
Vomiting
Increased heart rate (5-17 bpm observed)
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome history (class warning for GLP-1 agonists)
Pregnancy or breastfeeding (insufficient safety data)
Research Evidence
CJC-1295 with DAC Mazdutide
Status Well Studied Extensively Studied
References 4 studies 4 studies
Latest 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.